Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...

Patient enrollment is completed ahead of schedule for Contineum's Phase 2 clinical trial of PIPE-307, an oral remyelination ...

New research pinpoints genes associated with a disease seen as a major contributor to poor performance in Thoroughbred ...

Research shows that men's brains are 10-15% larger on average than women's. However, size does not impact intelligence. Men ...

Relapsing-remitting multiple sclerosis is an unpredictable disease marked by relapses and remissions, but there are options ...

Mistakes can often be the best teachers for young children. By creating a classroom environment where trying, stumbling, and trying again are celebrated, preschool educators empower children to build ...

Regular aerobic exercise could significantly reduce disease markers associated with Alzheimer's, new research led by scientists at the University of ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

A grant from the Rosenau Family Research Foundation will examine how an enzyme deficiency in the brain leads to this fatal ...

Discover the amazing benefits of Vitamin B12 for your body, how it boosts your energy, mental health, and more. Learn how to ...